Resources
About Us
Home Report
Store
Biomarkers Market
Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Efficacy, Validation, Safety) Mechanism (Genetic, Epigenetic, Proteomic) Technology (ELISA, Microarray, PCR, NGS), Offering, Application, Disease Type, End User – Global Forecast to 2031
Report ID:MRHC - 1041186 Pages: 350 May-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 HoursThe Biomarkers Market was valued at $69.76 billion in 2023. This market is expected to reach $201.33 billion by 2031, from an estimated $79 billion in 2024, at a CAGR of 14.3% during the forecast period 2024-2031.
Biomarkers Market Size & Forecast
The growth of this market can be attributed to various factors, such as the increasing pharmaceutical research spending, rising prevalence of target diseases, technological advancements in biomarker detection, rising focus on clinical research, increasing funding for biomarker research, rising focus on early disease diagnosis, and application of biomarkers in multiple research areas. Furthermore, a rising focus on companion diagnostics, ongoing research on biomarkers, and a shift toward precision oncology are expected to offer growth opportunities.
Biomarkers Market Growth Drivers
Rising Prevalence of Target Diseases
Biomarkers are either released by the human body in response to various diseases or by organs that are affected by the disease, such as tumors. Biomarkers are being used increasingly to detect several infectious and chronic diseases, such as cancer, neurological disorders, cardiovascular diseases, and others.
In the case of cancer, clinical biomarker testing involves the detection of molecules of DNA, protein metabolites, RNA, or transcription factors that are either produced by the tumor or as a response to the tumor. These biomarkers help in cancer diagnostics and also provide predictive and prognostic information to guide patient care. The prevalence of cardiovascular diseases, cancer, and infectious diseases is increasing. According to GLOBOCAN, the global prevalence of all types of cancer is expected to increase by 63.4% by 2045 from 2022. The rising prevalence of cancer is increasing the demand for biomarker testing.
Increasing Funding for Biomarker Research
Biomarker research has gained traction in recent years owing to its applications in early disease diagnosis. The key players operating in the market and government agencies are raising funding and providing grants for advancements in biomarkers research and testing. For instance,
- In November 2023, the Michael J. Fox Foundation (U.S.), a non-profit organization working on the treatment of Parkinson’s disease, provided Octave Bioscience, Inc. (U.S.) with a USD 10 million grant to discover, develop, and validate a custom protein biomarker panel to measure Parkinson’s disease activity and progression in the clinic.
- In August 2023, the National Comprehensive Cancer Network (U.S.), an alliance of 33 cancer centers in the U.S. in partnership with Fight Colorectal Cancer (U.S.), a patient empowerment organization and Pfizer Inc. (U.S.), announced new grants awarded to improve initiatives focused on optimizing biomarker-directed therapy in metastatic colorectal cancer.
Click here to: Get Free Sample Pages of this Report
Biomarkers Market Trends
Digital Biomarkers
Digital biomarkers are referred to as the objective, quantifiable behavioral and psychological data that is measured and collected with the help of digital devices such as ingestible, portables, implantable, or wearables. This data is used for the prediction of health-related outcomes. During drug discovery, digital biomarkers provide more scalability and flexibility than traditional methods; thus, many companies are focusing on the use of digital biomarkers. The digital biomarkers help pharmaceutical companies to provide supplementary data that can be used during clinical trials for accurate patient-centric metrics. Chugai Pharmaceutical Co., Ltd. (Japan), a subsidiary of F. Hoffmann-La Roche AG (Germany), is using digital biomarker technology to collect and analyze patient physiological data. The data is further used for drug development, understanding disease mechanisms, and visualizing patient outcomes.
Microfluidics in Biomarker Detection
Microfluidic immunoassay is majorly used for the detection of biomarkers associated with diseases for understanding disease mechanisms for drug development and disease detection. Microfluidic platforms provide real-time in situ detection of exosomes, proteins, and other biomarkers released during cell physiological processes, thus providing insights into cellular processes, which can be further used to understand the disease mechanism.
Microfluidic immunoassays are increasingly used for oncology and cardiovascular disease biomarker detection. At present, commercially available microfluidic immunoassays for detecting cardiac biomarker tests are based on the detection of cardiac troponins, natriuretic peptides (NPS), creatine kinase (CK-MB), D-Dimer, C-reactive protein (CRP), and myoglobin. The tests are available either for single biomarker analysis or in the form of multiplexed assay (panel tests) for the detection of more than one biomarker.
Biomarkers Market Opportunity
Increasing Focus on Companion Diagnostics
Companion diagnostics is a test used to match a patient with a specific therapy or drug. For instance, a companion diagnostic test detects a patient's tumor for a specific biomarker that is targeted by the drug. This helps determine whether the patient should receive the drug or not. The development of companion diagnostics begins with the discovery and validation of biomarkers. Thus, the emphasis on biomarker discovery and validation is increasing. Biomarkers in companion diagnostics contribute to more precise, efficient, and personalized healthcare delivery.
The rising focus on companion diagnostic research and recent approvals for companion diagnostics is increasing the demand for biomarkers. In October 2022, F. Hoffmann-La Roche AG (Switzerland) received U.S. FDA approval for PATHWAY anti-HER2 (4B5) test, a companion diagnostic test. The test is used for the assessment of HER2 low status in metastatic breast cancer patients.
Biomarkers Market Analysis: Key Findings
By Biomarker Type: In 2024, the Safety Biomarkers Segment to Dominate the Biomarkers Market
Based on biomarker type, the biomarkers market is segmented into efficacy biomarkers, validation biomarkers, and safety biomarkers. In 2024, the safety biomarkers segment is expected to account for the largest share of 42.4% of the biomarkers market. Safety biomarkers are used to assess the safety or potential risks after and before exposure to a medical product or environmental agent. The large share of the segment is attributed to the increase in drug discovery research and availability of funding. The key pharmaceutical manufacturers heavily invest in R&D. The companies like Roche (Switzerland), Novartis AG (Switzerland), Abbott (U.S.), and Merck (U.S.) are investing 15%-30% of their revenue annually dedicated to R&D. Thus, high spending on drug discovery is accelerating the demand for safety biomarkers.
However, the efficacy biomarkers segment is projected to witness the highest growth rate of 15.8% during the forecast period of 2024–2031. Efficacy biomarkers are used to assess the effectiveness or therapeutic response of a drug. These biomarkers help determine whether a treatment is producing desired effects or not. Growing number of clinical trials globally is driving the market growth. For instance, as per WHO data published in February 2023, the number of clinical trials in 2022 has reached 744,100 compared to 487,002 in 2019. Thus, the rise in the number of candidates in phases III and IV of clinical trials is driving market growth.
By Offering: In 2024, the Consumables Segment to Dominate the Biomarkers Market
Based on offering, the biomarkers market is segmented into consumables and services & software. In 2024, the consumables segment is expected to account for the largest share of the biomarkers market. The continuous advancements in terms of the development of reagents and kits, high adoption and recurring consumption of biomarker identification and testing kits, and wide availability of consumables support the largest share of the market. The adoption of biomarker kits in clinical diagnostics is high due to rising disease prevalence, thereby supporting the segment’s largest share.
By Mechanism: In 2024, the Epigenetic Biomarkers Segment to Dominate the Biomarkers Market
Based on mechanism, the biomarkers market is segmented into genetic biomarkers, epigenetic biomarkers, proteomic biomarkers, lipidomic biomarkers, and other mechanisms. In 2024, the epigenetic biomarkers segment is expected to account for the largest share of the biomarkers market. Epigenetic biomarkers are used to assess biological processes such as disease development, progression, and response to the treatment. The rise in the prevalence of infectious and non-infectious diseases, coupled with the rising need to bring novel therapies to the market, is generating demand for epigenetic markets.
The key players are also collaborating with other industry players to boost research in epigenetic markers. For instance, in November 2023, Bayer AG partnered with Hurdle (U.K.) to advance precision health and increase patients' access to novel epigenetic and multi-omics for at-home biomarker tests.
By Profiling Technology: In 2024, the Immunoassay Segment to Dominate the Biomarkers Market
Based on profiling technology, the biomarkers market is segmented into immunoassay, NGS, PCR, mass spectrometry, chromatography, and other technologies. In 2024, the immunoassay segment is expected to account for the largest share of the biomarkers market. Immunoassays are bioanalytical techniques that use the specificity of an antigen-antibody reaction to detect and quantify target molecules in biological samples. The wide utilization of immunoassays in clinical diagnostics, drug discovery, and drug monitoring for biomarker detection contributes to the largest share of the market. Immunoassays are fast, simple, and a cost-effective technique, with better sensitivity and specificity comparable to or better than the conventional methods, owing to which their adoption is the highest.
By Disease Type: In 2024, the Oncology Segment to Dominate the Biomarkers Market
Based on disease type, the biomarkers market is segmented into oncology, cardiovascular diseases, infectious diseases, neurological disorders, diabetes and other metabolic diseases, and other diseases. In 2024, the oncology segment is expected to account for the largest share of the biomarkers market. In cancer research, biomarkers are used for wide applications such as early detection, diagnosis, prognosis, and treatment. Cancer (malignant tumor) is a major health concern globally and is one of the leading causes of morbidity and mortality across the world. According to GLOBOCAN, the number of all cancer types diagnosed in 2020 was 19.29 million, and it is expected to reach 24.59 million by 2030. The evolving landscape of biomarker research in cancer and the availability of funding to support cancer research are supporting the segment’s largest share.
By Application: In 2024, the Drug Discovery & Development Segment to Dominate the Biomarkers Market
Based on application, the biomarkers market is segmented into diagnostics, drug discovery & development, personalized medicine, clinical research, and other applications. In 2024, the drug discovery & development segment is expected to account for the largest share of 33% of the biomarkers market. The largest share of the segment is attributed to the wide applications of biomarkers in research & development, focus on developing precision therapeutics, and high growth in the cancer biomarker research supports the largest share of the market. The rising funding for drug discovery and the increasing need for developing novel therapies are supporting the largest share of the segment. For instance, in June 2023, the Commonwealth Government’s Medical Research Future Fund (MRFF) (Australia) invested USD 9.75 million in establishing MedChem Australia, a new national medicinal chemistry initiative, to accelerate the identification of early-stage drug candidates in clinical studies.
However, the diagnostics segment is projected to witness the highest growth rate of 16.0% during the forecast period of 2024–2031. The high growth of the segment is attributed to the increasing use of biomarkers in disease risk assessment, staging to categorize disease severity, treatment selection, and patient monitoring. The rising prevalence of infectious and non-infectious diseases, coupled with the availability of funding for clinical diagnostics, are supporting the segment’s high growth. For instance, in April 2024, the U.S. National Science Foundation awarded a USD 275,000 Phase 1 Small Business Innovation Research (SBIR) grant to Amplified Sciences, a clinical-stage life sciences diagnostic company based in the U.S. The company is developing tests for early, more accurate detection of challenging diseases such as pancreatic cancer.
By End User: In 2024, the Pharmaceutical & Biotechnology Companies Segment to Dominate the Biomarkers Market
Based on end user, the biomarkers market is segmented into pharmaceutical & biotechnology companies, hospitals, diagnostic laboratories, and other end users. In 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the biomarkers market. The largest share of the segment is attributed to high spending on R&D by pharmaceutical companies, a focus on developing novel therapies, and a growing focus on personalized medicines.
Pharmaceutical and biotechnology companies allocate significant resources to their research activities. The rising spending on R&D by pharmaceutical companies is contributing to the largest share of the market. For instance, in 2021, Pharmaceutical Research and Manufacturers of America (PhRMA) member companies spent USD 102.3 billion in R&D, compared to USD 91.1 Billion in 2020 (Source: 2022 PhRMA member annual survey).
Geographical Analysis
In 2024, North America is expected to account for the largest share of the 49.2% of the biomarkers market. The large share of the region is attributed to the substantial R&D investments by pharmaceutical companies for drug discovery & development, the presence of key market players in the region, government initiatives supporting research and development, and the high adoption of advanced diagnostic products. The regional government is focusing on biomarker research, further supporting the largest share in the region. For instance, in June 2023, the FDA launched a voluntary pilot program using cancer biomarkers for certain oncology drug products with certain corresponding in-vitro diagnostic tests. The program aims to help clinicians select suitable cancer treatments for patients.
Moreover, the market in Asia-Pacific is slated to register the highest growth rate of 17.2% during the forecast period. The countries in Asia-Pacific, including China, India, and South Korea, are projected to offer significant growth opportunities for the vendors in this market. The growing prevalence of diseases due to the growing geriatric population, increasing funding for drug discovery, and rising research initiatives for biomarkers in the country are driving the market growth. For instance, in October 2023, the Indian Institute of Technology (IIT), Madras, India, established a Centre of Excellence for research purposes to develop biomarkers for early detection of pancreatic cancer. Similarly, in May 2023, Fujitsu Limited (Japan), Kyoto University (Japan), and Chordia Therapeutics, Inc. (Japan) launched AI trials to discover biomarkers for new cancer drugs.
Biomarkers Market: Key Companies
The report offers a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past few years (2020–2024). The key players operating in the global biomarkers market are F. Hoffmann-La Roche AG (Switzerland), Merck KGaA (Germany), Epigenomics AG (Germany), Abbott Laboratories (U.S.), QIAGEN N.V. (Germany), Bio-Rad Laboratories (U.S.), Revvity Inc. (U.S.), Siemens Healthineers AG (Germany), Mindray (China), Thermo Fisher Scientific Inc. (U.S.), Eurofins Scientific SE (France), bioMérieux SA (France), Agilent Technologies, Inc. (U.S.), and Quanterix Corp. (U.S.).
Biomarkers Market Overview: Latest Developments from Key Industry Players
- In March 2024, Labcorp (U.S.) launched a pTau217 blood biomarker test. The test helps diagnose Alzheimer's disease and monitor patients undergoing treatment with new therapies.
- In January 2024, Merck KGaA (Germany) partnered with Quibim (Spain) to develop precision medicine technology for the treatment of a wide range of cancers. Both companies are using radiomics and biomarkers to predict a cancer patient’s response to immunotherapy.
- In October 2023, Mindray (China) launched a high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarker assay for the diagnosis of cardiovascular diseases. The launch enhances Mindray’s diverse portfolio of cardiac biomarkers.
- In July 2023, Quanterix Corp. (U.S.) launched a LucentAD biomarker blood test. The test evaluates patients experiencing cognitive symptoms consistent with the early signs of Alzheimer’s disease (AD).
- In June 2023, Sysmex Corporation (Japan) launched a HISCL β-Amyloid 1-42 Assay Kit and the HISCL β-Amyloid 1-40 assay kit for the diagnosis of Alzheimer’s Disease. The product helps in detecting the level of accumulation of Aβ in the brain by measuring the ratio of Aβ peptides, which are blood biomarkers approved as in vitro diagnostics.
Biomarkers Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
350 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
14.3% |
|
Estimated Market Size (Value) |
$201.33 billion by 2031 |
|
Segments Covered |
By Biomarker Type
By Offering
By Mechanism
By Profiling Technology
By Disease Type
By Application
By End User
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Belgium, Netherlands, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Latin America, and Middle East & Africa |
|
Key Companies |
The key players operating in the biomarkers market are F. Hoffmann-La Roche AG (Switzerland), Merck KGaA (Germany), Epigenomics AG (Germany), Abbott Laboratories (U.S.), QIAGEN N.V. (Germany), Bio-Rad Laboratories (U.S.), Revvity Inc (U.S.), Siemens Healthineers AG (Germany), Mindray (China), Thermo Fisher Scientific Inc. (U.S.), Eurofins Scientific SE (France), bioMérieux SA (France), Agilent Technologies, Inc. (U.S.), and Quanterix Corp. (U.S.). |
Key questions answered in the biomarkers market report:
The Biomarkers Market focuses on identifying biological markers for disease detection, diagnosis, drug development, and personalized medicine approaches.
The Biomarkers Market was valued at $69.76 Billion in 2023 and is projected to reach $201.33 Billion by 2031, showing significant future growth.
The market is projected to reach $201.33 billion by 2031, growing at a robust CAGR of 14.3% from 2024 to 2031, driven by advances in diagnostics.
The Biomarkers Market is estimated at $79 Billion in 2024 and is expected to grow to $201.33 Billion by 2031, driven by advancements in research and diagnostics.
Key players include Roche, Merck, Abbott, QIAGEN, Thermo Fisher Scientific, Siemens Healthineers, and Quanterix, focusing on biomarker development and analysis.
The market trends include a move toward digital biomarkers, microfluidic technology, and companion diagnostics, promoting advancements in personalized healthcare.
Rising disease prevalence, increased research funding, growing emphasis on personalized medicine, and technological advances in biomarker detection drive market growth.
Market segments include biomarker type, offerings (kits, services), mechanisms, profiling technologies, disease types, applications, and end users like hospitals and labs.
Globally, North America leads with the highest market share, while the Asia-Pacific region is expected to show the fastest growth due to increased healthcare investments.
Biomarkers Market growth is fueled by increasing R&D investments, the rising burden of chronic diseases, and technological innovations in diagnostic platforms.
The market is projected to grow at a CAGR of 14.3% during 2024–2031, indicating steady growth due to advancements in precision medicine and diagnostic tools.
North America leads with the highest market share of 49.2% in 2024, driven by significant investments in R&D, healthcare infrastructure, and diagnostic technologies.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Increasing Pharmaceutical Research Spending
4.2.2. Rising Prevalence of Target Diseases
4.2.3. Technological Advancements in Biomarker Detection
4.2.4. Rising Focus on Clinical Research
4.2.5. Increasing Funding for Biomarker Research
4.2.6. Rising Focus on Early Disease Diagnosis
4.2.7. Applications of Biomarkers in Multiple Areas
4.3. Restraints
4.3.1. High Capital Investment for Biomarker Discovery
4.3.2. Lengthy Timeline for Biomarker Development
4.4. Opportunities
4.4.1. Rising Funding for R&D
4.4.2 Rising Focus on Companion Diagnostics
4.4.3. Ongoing Research on Biomarkers
4.4.4. Shift Towards Precision Oncology
4.5. Challenges
4.5.1. Challenges Associated with Biomarkers Validation
4.5.2. Technical Issues Related to Sample Collection and Storage
4.6. Factor Analysis
4.7. Trends
4.8. Regulatory Analysis
4.9. Porter’s Five Force Analysis
5. Biomarkers Market Assessment—by Biomarker Type
5.1. Overview
5.2. Efficacy Biomarkers
5.2.1. Prognostic Biomarkers
5.2.2. Pharmacodynamic Biomarkers
5.2.3. Surrogate Biomarkers
5.2.4. Predictive Biomarkers
5.3. Validation Biomarkers
5.4. Safety Biomarkers
6. Biomarkers Market Assessment—by Offerings
6.1. Overview
6.2. Consumables
6.2.1. Assay Kits
6.2.2. Reagents
6.2.3. Other Consumables
6.3. Services & Software
7. Biomarkers Market Assessment—by Mechanism
7.1. Overview
7.2. Genetic Biomarkers
7.3. Epigenetic Biomarkers
7.4. Proteomic Biomarkers
7.5. Lipidomic Biomarkers
7.6. Other Mechanisms
8. Biomarkers Market Assessment—by Profiling Technology
8.1. Overview
8.2. Immunoassay
8.2.1. ELISA
8.2.2. Western Blot
8.2.3. Protein Microarray
8.3. NGS
8.4. PCR
8.5. Mass Spectrometry
8.6. Chromatography
8.7. Other Technologies
9. Biomarkers Market Assessment—by Disease Type
9.1. Overview
9.2. Oncology
9.3. Cardiovascular Diseases
9.4. Infectious Diseases
9.5. Neurological Disorders
9.6. Diabetes and Other Metabolic Diseases
9.7. Other Diseases
10. Biomarkers Market Assessment—by Application
10.1. Overview
10.2. Diagnostics
10.3. Drug Discovery and Development
10.4. Personalized Medicine
10.5. Clinical Research
10.6. Other Applications
11. Biomarkers Market Assessment—by End User
11.1. Overview
11.2. Pharmaceutical & Biotechnology Companies
11.3. Hospitals
11.4. Diagnostic Laboratories
11.5. Other End Users
12. Biomarkers Market Assessment—by Geography
12.1. Overview
12.2. North America
12.2.1. U.S.
12.2.2. Canada
12.3. Europe
12.3.1. Germany
12.3.2. France
12.3.3. U.K.
12.3.4. Italy
12.3.5. Spain
12.3.6. Switzerland
12.3.7. Belgium
12.3.8. Netherlands
12.3.9. Rest of Europe (RoE)
12.4. Asia-Pacific
12.4.1. Japan
12.4.2. China
12.4.3. India
12.4.4. South Korea
12.4.5. Rest of Asia-Pacific (RoAPAC)
12.5. Latin America
12.6. Middle East & Africa
13. Competition Analysis
13.1. Overview
13.2. Key Growth Strategies
13.3. Competitive Benchmarking
13.4. Competitive Dashboard
13.4.1. Industry Leaders
13.4.2. Market Differentiators
13.4.3. Vanguards
13.4.4. Emerging Companies
13.5. Market Share Analysis/Market Ranking, by Key Players (2023)
14. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)
14.1. F. Hoffmann-La Roche AG
14.2. Merck KGaA
14.3. Epigenomics AG
14.4. Abbott Laboratories
14.5. QIAGEN N.V.
14.6. Bio-Rad Laboratories
14.7. Revvity Inc.
14.8. Siemens Healthineers AG
14.9. Mindray
14.10. Eurofins Scientific SE
14.11. bioMérieux SA
14.12. Agilent Technologies, Inc.
14.13. Quanterix Corp.
14.14. Thermo Fisher Scientific Inc.
(Note: SWOT analysis of the top 5 companies will be provided.)
15. Appendix
15.1. Available Customization
15.2. Related Reports
List of Tables
Table 1 Global Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 2 Global Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 3 Global Efficacy Biomarkers Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Global Prognostic Biomarkers Market, by Country/Region, 2022–2031 (USD Million)
Table 5 Global Pharmacodynamic Biomarkers Market, by Country/Region, 2022–2031 (USD Million)
Table 6 Global Surrogate Biomarkers Market, by Country/Region, 2022–2031 (USD Million)
Table 7 Global Predictive Biomarkers Market, by Country/Region, 2022–2031 (USD Million)
Table 8 Global Validation Biomarkers Market, by Country/Region, 2022–2031 (USD Million)
Table 9 Global Safety Biomarkers Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Global Biomarkers Market, by Offerings, 2022–2031 (USD Million)
Table 11 Global Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 12 Global Biomarkers Market for Consumables, by Country/Region, 2022–2031 (USD Million)
Table 13 Global Biomarkers Market for Assay Kits, by Country/Region, 2022–2031 (USD Million)
Table 14 Global Biomarkers Market for Reagents, by Country/Region, 2022–2031 (USD Million)
Table 15 Global Biomarkers Market for Other Consumables, by Country/Region, 2022–2031 (USD Million)
Table 16 Global Biomarkers Market for Services & Software, by Country/Region, 2022–2031 (USD Million)
Table 17 Global Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 18 Global Genetic Biomarkers Market, by Country/Region, 2022–2031 (USD Million)
Table 19 Global Epigenetic Biomarkers Market, by Country/Region, 2022–2031 (USD Million)
Table 20 Global Proteomic Biomarkers Market, by Country/Region, 2022–2031 (USD Million)
Table 21 Global Lipidomic Biomarkers Market, by Country/Region, 2022–2031 (USD Million)
Table 22 Global Biomarkers Market for Other Mechanisms, by Country/Region, 2022–2031 (USD Million)
Table 23 Global Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 24 Global Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 25 Global Biomarkers Market for Immunoassay, by Country/Region, 2022–2031 (USD Million)
Table 26 Global Biomarkers Market for ELISA, by Country/Region, 2022–2031 (USD Million)
Table 27 Global Biomarkers Market for Western Blot, by Country/Region, 2022–2031 (USD Million)
Table 28 Global Biomarkers Market for Protein Microarray, by Country/Region, 2022–2031 (USD Million)
Table 29 Global Biomarkers Market for NGS, by Country/Region, 2022–2031 (USD Million)
Table 30 Global Biomarkers Market for PCR, by Country/Region, 2022–2031 (USD Million)
Table 31 Global Biomarkers Market for Mass Spectrometry, by Country/Region, 2022–2031 (USD Million)
Table 32 Global Biomarkers Market for Chromatography, by Country/Region, 2022–2031 (USD Million)
Table 33 Global Biomarkers Market for Other Technologies, by Country/Region, 2022–2031 (USD Million)
Table 34 Global Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 35 Global Biomarkers Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 36 Global Biomarkers Market for Cardiovascular Diseases, by Country/Region, 2022–2031 (USD Million)
Table 37 Global Biomarkers Market for Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
Table 38 Global Biomarkers Market for Neurological Disorders, by Country/Region, 2022–2031 (USD Million)
Table 39 Global Biomarkers Market for Diabetes and Other Metabolic Diseases, by Country/Region, 2022–2031 (USD Million)
Table 40 Global Biomarkers Market for Other Diseases, by Country/Region, 2022–2031 (USD Million)
Table 41 Global Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 42 Global Biomarkers Market for Diagnostics, by Country/Region, 2022–2031 (USD Million)
Table 43 Global Biomarkers Market for Drug Discovery and Development, by Country/Region, 2022–2031 (USD Million)
Table 44 Global Biomarkers Market for Personalized Medicine, by Country/Region, 2022–2031 (USD Million)
Table 45 Global Biomarkers Market for Clinical Research, by Country/Region, 2022–2031 (USD Million)
Table 46 Global Biomarkers Market for Other Applications, by Country/Region, 2022–2031 (USD Million)
Table 47 Global Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 48 Global Biomarkers Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022–2031 (USD Million)
Table 49 Global Biomarkers Market for Hospitals, by Country/Region, 2022–2031 (USD Million)
Table 50 Global Biomarkers Market for Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 51 Global Biomarkers Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 52 Global Biomarkers Market, by Country/Region, 2022–2031 (USD Million)
Table 53 North America: Biomarkers Market, by Country, 2022–2031 (USD Million)
Table 54 North America: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 55 North America: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 56 North America: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 57 North America: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 58 North America: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 59 North America: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 60 North America: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 61 North America: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 62 North America: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 63 North America: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 64 U.S.: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 65 U.S.: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 66 U.S.: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 67 U.S.: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 68 U.S.: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 69 U.S.: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 70 U.S.: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 71 U.S.: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 72 U.S.: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 73 U.S.: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 74 Canada: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 75 Canada: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 76 Canada: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 77 Canada: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 78 Canada: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 79 Canada: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 80 Canada: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 81 Canada: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 82 Canada: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 83 Canada: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 84 Europe: Biomarkers Market, by Country/Region, 2022–2031 (USD Million)
Table 85 Europe: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 86 Europe: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 87 Europe: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 88 Europe: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 89 Europe: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 90 Europe: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 91 Europe: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 92 Europe: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 93 Europe: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 94 Europe: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 95 Germany: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 96 Germany: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 97 Germany: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 98 Germany: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 99 Germany: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 100 Germany: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 101 Germany: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 102 Germany: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 103 Germany: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 104 Germany: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 105 France: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 106 France: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 107 France: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 108 France: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 109 France: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 110 France: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 111 France: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 112 France: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 113 France: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 114 France: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 115 U.K.: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 116 U.K.: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 117 U.K.: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 118 U.K.: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 119 U.K.: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 120 U.K.: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 121 U.K.: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 122 U.K.: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 123 U.K.: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 124 U.K.: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 125 Italy: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 126 Italy: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 127 Italy: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 128 Italy: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 129 Italy: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 130 Italy: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 131 Italy: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 132 Italy: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 133 Italy: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 134 Italy: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 135 Spain: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 136 Spain: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 137 Spain: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 138 Spain: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 139 Spain: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 140 Spain: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 141 Spain: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 142 Spain: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 143 Spain: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 144 Spain: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 145 Switzerland: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 146 Switzerland: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 147 Switzerland: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 148 Switzerland: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 149 Switzerland: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 150 Switzerland: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 151 Switzerland: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 152 Switzerland: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 153 Switzerland: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 154 Switzerland: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 155 Belgium: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 156 Belgium: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 157 Belgium: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 158 Belgium: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 159 Belgium: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 160 Belgium: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 161 Belgium: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 162 Belgium: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 163 Belgium: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 164 Belgium: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 165 Netherlands: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 166 Netherlands: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 167 Netherlands: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 168 Netherlands: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 169 Netherlands: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 170 Netherlands: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 171 Netherlands: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 172 Netherlands: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 173 Netherlands: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 174 Netherlands: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 175 Rest of Europe: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 176 Rest of Europe: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 177 Rest of Europe: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 178 Rest of Europe: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 179 Rest of Europe: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 180 Rest of Europe: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 181 Rest of Europe: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 182 Rest of Europe: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 183 Rest of Europe: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 184 Rest of Europe: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 185 Asia-Pacific: Biomarkers Market, by Country/Region, 2022–2031 (USD Million)
Table 186 Asia-Pacific: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 187 Asia-Pacific: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 188 Asia-Pacific: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 189 Asia-Pacific: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 190 Asia-Pacific: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 191 Asia-Pacific: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 192 Asia-Pacific: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 193 Asia-Pacific: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 194 Asia-Pacific: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 195 Asia-Pacific: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 196 China: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 197 China: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 198 China: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 199 China: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 200 China: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 201 China: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 202 China: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 203 China: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 204 China: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 205 China: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 206 Japan: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 207 Japan: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 208 Japan: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 209 Japan: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 210 Japan: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 211 Japan: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 212 Japan: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 213 Japan: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 214 Japan: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 215 Japan: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 216 India: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 217 India: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 218 India: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 219 India: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 220 India: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 221 India: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 222 India: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 223 India: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 224 India: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 225 India: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 226 South Korea: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 227 South Korea: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 228 South Korea: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 229 South Korea: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 230 South Korea: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 231 South Korea: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 232 South Korea: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 233 South Korea: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 234 South Korea: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 235 South Korea: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 236 Rest of Asia-Pacific: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 237 Rest of Asia-Pacific: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 238 Rest of Asia-Pacific: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 239 Rest of Asia-Pacific: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 240 Rest of Asia-Pacific: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 241 Rest of Asia-Pacific: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 242 Rest of Asia-Pacific: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 243 Rest of Asia-Pacific: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 244 Rest of Asia-Pacific: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 245 Rest of Asia-Pacific: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 246 Latin America: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 247 Latin America: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 248 Latin America: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 249 Latin America: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 250 Latin America: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 251 Latin America: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 252 Latin America: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 253 Latin America: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 254 Latin America: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 255 Latin America: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 256 Middle East & Africa: Biomarkers Market, by Biomarker Type, 2022–2031 (USD Million)
Table 257 Middle East & Africa: Efficacy Biomarkers Market, by Type, 2022–2031 (USD Million)
Table 258 Middle East & Africa: Biomarkers Market, by Offering, 2022–2031 (USD Million)
Table 259 Middle East & Africa: Biomarkers Market for Consumables, by Type, 2022–2031 (USD Million)
Table 260 Middle East & Africa: Biomarkers Market, by Mechanism, 2022–2031 (USD Million)
Table 261 Middle East & Africa: Biomarkers Market, by Profiling Technology, 2022–2031 (USD Million)
Table 262 Middle East & Africa: Biomarkers Market for Immunoassay, by Type, 2022–2031 (USD Million)
Table 263 Middle East & Africa: Biomarkers Market, by Disease Type, 2022–2031 (USD Million)
Table 264 Middle East & Africa: Biomarkers Market, by Application, 2022–2031 (USD Million)
Table 265 Middle East & Africa: Biomarkers Market, by End User, 2022–2031 (USD Million)
Table 266 Recent Developments, by Company, 2020–2024
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Global Biomarkers Market, by Biomarker Type, 2024 VS. 2031 (USD Million)
Figure 8 Global Biomarkers Market, by Offering, 2024 VS. 2031 (USD Million)
Figure 9 Global Biomarkers Market, by Mechanism, 2024 VS. 2031 (USD Million)
Figure 10 Global Biomarkers Market, by Profiling Technology, 2024 VS. 2031 (USD Million)
Figure 11 Global Biomarkers Market, by Disease Type, 2024 VS. 2031 (USD Million)
Figure 12 Global Biomarkers Market, by Application, 2024 VS. 2031 (USD Million)
Figure 13 Global Biomarkers Market, by End User, 2024 VS. 2031 (USD Million)
Figure 14 Global Biomarkers Market, by Geography
Figure 15 Global Biomarkers Market, by Biomarker Type, 2024 VS. 2031 (USD Million)
Figure 16 Global Biomarkers Market, by Offering, 2024 VS. 2031 (USD Million)
Figure 17 Global Biomarkers Market, by Mechanism, 2024 VS. 2031 (USD Million)
Figure 18 Global Biomarkers Market, by Profiling Technology, 2024 VS. 2031 (USD Million)
Figure 19 Global Biomarkers Market, by Disease Type, 2024 VS. 2031 (USD Million)
Figure 20 Global Biomarkers Market, by Application, 2024 VS. 2031 (USD Million)
Figure 21 Global Biomarkers Market, by End User, 2024 VS. 2031 (USD Million)
Figure 22 Global Biomarkers Market, by Geography, 2024 VS. 2031 (USD Million)
Figure 23 North America: Biomarkers Market Snapshot
Figure 24 Europe: Biomarkers Market Snapshot
Figure 25 Asia-Pacific: Biomarkers Market Snapshot
Figure 26 Key Growth Strategies Adopted by Leading Players, 2020–2024
Figure 27 Global Biomarkers Market: Competitive Benchmarking, by Offerings
Figure 28 Global Biomarkers Market: Competitive Benchmarking, by Geography
Figure 29 Global Biomarkers Market: Competitive Dashboard
Figure 30 Global Biomarkers Market: Market Share Analysis/Market Ranking (2023)
Figure 31 F. Hoffmann-La Roche AG: Financial Snapshot (2023)
Figure 32 Merck KGaA: Financial Snapshot (2023)
Figure 33 Epigenomics AG: Financial Snapshot (2023)
Figure 34 Abbott Laboratories: Financial Snapshot (2023)
Figure 35 QIAGEN N.V.: Financial Snapshot (2023)
Figure 36 Bio-Rad Laboratories: Financial Snapshot (2023)
Figure 37 Revvity Inc.: Financial Snapshot (2023)
Figure 38 Siemens Healthineers AG: Financial Snapshot (2023)
Figure 39 Mindray: Financial Snapshot (2023)
Figure 40 Eurofins Scientific SE: Financial Snapshot (2023)
Figure 41 bioMérieux SA: Financial Snapshot (2023)
Figure 42 Agilent Technologies, Inc.: Financial Snapshot (2023)
Figure 43 Quanterix Corp.: Financial Snapshot (2023)
Figure 44 Thermo Fisher Scientific Inc: Financial Snapshot (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Cancer/Tumor Profiling Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jul-2024
Microfluidic Immunoassay Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jan-2024
Tissue Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2022-2029)
Published Date: Nov-2022
